Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory support.
ARIAD retains the option to file for marketing authorization at a later date and, if approved, to hold the Marketing Authorization for Iclusig in Turkey.
Gen Ilac has the exclusive right then to market and commercialize the product upon approval.
"This agreement with Gen Ilac furthers our mission to provide Iclusig to patients in geographies beyond our core commercial footprint," said Marty J. Duvall, executive vice president and chief commercial officer of ARIAD.
"We are excited by Gen Ilac’s experience and proven capabilities in this area, which makes them an ideal partner to introduce Iclusig to patients and physicians in Turkey."
"We are excited by our partnership with ARIAD and the hope it provides to refractory CML patients in Turkey," said Abidin Gulmus, chief executive officer of GEN ILAC.
"This partnership aligns well with our company mission and our expertise in providing treatments in the field of hematology."